Trimodal therapy vs radical cystectomy in patients with muscle-invasive #BladderCancer : a systematic review and meta-analysis
Francesco Ditonno Alessandro Veccia Celeste Manfredi Alexander Kutikov MD Riccardo Autorino MD PhD Alessandro Antonelli

doi.org/10.1111/bju.16…

Generally a fan of #EAU #ESTRO etc guidelines. But curious why focal RT boost of tumor gets “weak” rating and ePLND gets “strong” 🤔

Only one of these has phase 3 RCT evidence of ⬇️ recurrence, ⬆️nodal/distant MFS, w/o toxicity increase.

Reconsider for 2025? ESTRO European Association of Urology (EAU)

I’m excited to announce I will be speaking at the @lungevity #HOPESummit in Atlanta May 3-5!

Join me for a weekend of community, support & hope for those affected by #lungcancer

Register for free: lungevity.org/hopesummit24

#ThisIsHOPE24 #HOPESummit 24 #radonc #lcsm Northside Hospital Network Providers

Just a day or so late 😂

Check out that KM curve for SANO-1 trial of EsoCa (SCC or Adeno) with cCR after CRT randomized to surgery or active surveillance

🔥Non-inf OS and ⬆️QoL with AS

SANO-2 and ESOSTRATE will clarify further
rb.gy/t8j2ep
rb.gy/y3bjbw

After the OS ⬆️ of RT to the prostate in STAMPEDE Arm H for low volume metastatic PCa, should it now be SOC for both low and high volume after PEACE-1 demonstrated ⬇️ serious GU symptoms in the era of systemic intensification? Excellent presentation from Sandy Srinivas. #APCCC24 …

FTC bans non-compete clauses in contracts, including for physicians.

ftc.gov/news-events/ne…

#EAU24 PEACE V-STORM: Ph 2 RCT of salvage MDT + 6 mo ADT +/- ENRT for Oligorecurrent nodal PCa: 24-mo toxicity results Thomas Zilli
UroToday.com

n=97, MDT vs n=93, ENRT
📌Worst late Gr ≥ 2 GI AEs: 5.3% vs 6.6% (p=0.94)
📌Worst late GU ≥ 2 GU AEs: 22.2% vs 26.5% (p=0.61)

1/ The long-awaited OS results from #KEYNOTE -564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC .

nejm.org/doi/full/10.10…

💊 ❌ Majority of cancer drugs approved in the FDAs accelerated approval pathway do not improve patient survival or QOL

Important reminder for KOLs to honestly evaluate trial results & limitations

JAMA Eddie Cliff

#MedTwitter #oncology

jamanetwork.com/journals/jama/…

Delighted to present our work at #AACR24 today, led by Ian Liu, on oncology accelerated approvals, simultaneously published JAMA

Accelerated approval is a useful program but has a long way to go to ensure it delivers high-value drugs

jamanetwork.com/journals/jama/…

Study out on ASTRO 🇺🇸Advances in #RadOnc ☢️ delves into efficacy & safety of stereotactic radiosurgery for ≥15 brain metastases🧠

✅Revealing favorable outcomes & improved cognition vs. whole brain radiation therapy (WBRT)
✅W/ longer median survival, SRS emerges as a…

Getting excited about benign radiotherapy! - Simul Parikh
ACRO - American College of Radiation Oncology Bobby Koneru, MD Mudit Chowdhary, MD Jona Hattangadi-Gluth, MD

#ASTRO #ASTRO News #Cancer #MusculoskeletalPain #OncoDaily #Oncology #Radiotherapy

oncodaily.com/47106.html

No SUNSET on this ultracentral trial of 60 Gy in 8 fractions
<7% grade 3-5 AEs, ~90% local control
Online at: redjournal.org/article/S0360-…
Meredith Giuliani Benjamin Lok, MD Alex Louie MD, PhD Houda Bahig, MD PhD Andrea Bezjak Scott Bratman Dr. David Palma

Total solar eclipse in Cleveland. Happy to have a short down time in between cases to capture this! Cleveland Clinic

DOSIS - RCT in pts with painful vertebral mets
Hypothesis: improved LC -> durable pain response
First randomized trial with 6 mo pain reduction as prim endpoint
N=63 pts randomized to SBRT vs conv. RT
Significant benefit of SBRT: 69.4% vs. 41.9% (p=0.02)
doi.org/10.1002/cncr.3…

If you aren’t cheating, you aren’t trying!

Are you looking at MRIs?

Feeling some confusion about the diffusion?

Feel impaired when it comes to the FLAIR?

Wish you could cheat a little?

Here’s a little cheat sheet on all the sequences you NEED to know if you are looking at…

🔥Big News

Press Release: Ph III ADRIATIC Trial meets OS & PFS Endpoints for Durva v Placebo in Limited Stage SCLC:

- 730pts with LS-SCLC post cCRT
- pts randomised to Durva +/- Treme post cCRT v pbo

Can't wait to see the full data
OncoAlert #LCSM
astrazeneca.com/media-centre/p…

Focal boost for #prostatecancer
IJROBP - The Red Journal home of all of the amazing things you can do with radiation
redjournal.org/article/S0360-…

Retrospective study NSCLC pts brain-only M+
- 103 pts: SRS of brain mets in all pts, definitive Tx of primary in 51%
- Local TX of primary associated with ⬆️ PFS & OS
- MVA for OS: definitive TX of primary, TX with IO, and AJCC stage
👏 Beaumont Radiation Oncology
thegreenjournal.com/article/S0167-…

Dr. Antoinette Wozniak with an EXCELLENT discussion of the exploding peri-operative space in resectable NSCLC at IASLC Best of #TTLC24 webinar. What will push us toward neoadj vs perioperative? pCR? MRD? impt research questions that need answering.